Nurix Therapeutics, Inc.
NASDAQNRIX cost to borrow surges to 1.91%, up 282% in one week amid tight share availability and sustained short pressure.
Snapshot as of 29 Jun 2026
Nurix Therapeutics enters the week with a sharp contradiction at its core: Needham just raised its price target to $34, yet the stock has shed 18% in the past five days to close at $14.64 — leaving analysts…
Nurix Therapeutics heads into today's earnings print as one of the more heavily shorted names in clinical-stage biotech, with short sellers retaining a firm grip on the stock. Short interest is running at roughly 21.9%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NRIX — free to start on ORTEX.
Sign up for free →Open NRIX on ORTEX